JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A Comprehensive Review on Transdermal Drug Delivery Systems (TDDS)

[1] Lokesh Sharma, [2] Dr Reena Singh, [3] Sandhya Sharma
[1] Research Scholar, [2] Associate Professor, [3] Assistant Professor
[1]Dept.of Pharmaceutics,
[1]Innovative College of Pharmacy, Geater Noida, India

Abstract : The transdermal drug delivery system (TDDS) has emerged as a significant advancement in pharmaceutical sciences, offering a non-invasive route for systemic drug administration. By circumventing the gastrointestinal tract and hepatic first-pass metabolism, TDDS provides controlled and sustained drug release. This review elaborates on its mechanisms, components, advantages, limitations, types, recent innovations, and applications, with references supporting each statement.
Key words: Buccal delivery, Mucoadhesive polymers, Drug bioavailability, First-pass metabolism avoidance.

I. INTRODUCTION

1. Introduction to Transdermal Drug Delivery Systems

TDDS refers to the administration of drugs through the skin to achieve systemic therapeutic effects. This method avoids the disadvantages of oral and parenteral drug delivery, such as gastrointestinal irritation, enzymatic degradation, and patient discomfort associated with injections【1】. The primary goal of TDDS is to deliver drugs at a controlled rate, maintaining consistent plasma concentrations【2】.

2. The Skin: An Anatomical Barrier to Drug Delivery

The skin serves as the largest organ of the human body, covering approximately 1.5 to 2 m^2 in adults【3】. It consists of three main layers:

1. **Epidermis:** The outermost layer, with the stratum corneum acting as the principal barrier to drug penetration【4】.
2. **Dermis:** A connective tissue layer rich in blood vessels and lymphatics, which facilitates systemic absorption【5】.
3. **Hypodermis:** A fatty layer that provides cushioning and energy storage【6】.

Drug penetration through the skin occurs via three primary pathways: transcellular (through cells), intercellular (between cells), and appendageal (through hair follicles and sweat glands)【7】.

3. Mechanism of Transdermal Drug Absorption

Transdermal absorption is a passive diffusion process governed by Fick's first law, where the drug moves from a high-concentration area (the formulation) to a low-concentration area (systemic circulation)【8】. Factors influencing drug absorption include:

- **Molecular weight:** Ideal drugs for TDDS have molecular weights below 500 Da【9】.
- **Partition coefficient:** Drugs must have balanced lipophilicity to penetrate the lipid-rich stratum corneum and reach the hydrophilic dermis【10】.
- **Skin hydration:** Increased hydration enhances drug permeation by loosening the lipid matrix of the stratum corneum【11】.

4. Components of Transdermal Drug Delivery Systems

TDDS typically comprises the following:

1. **Drug reservoir or matrix:** Stores and stabilizes the drug【12】.
2. **Rate-controlling membrane:** Regulates drug diffusion into the skin【13】.
3. **Adhesive layer:** Maintains contact with the skin and often contains the drug for immediate release【14】.
4. **Backing layer:** Provides mechanical support and protects the formulation from environmental exposure【15】.
5. **Release liner:** Covers the adhesive before application, preventing contamination【16】.

5. Advantages of TDDS

TDDS offers several advantages:

- **Avoidance of first-pass metabolism:** Bypasses hepatic drug degradation, improving bioavailability【17】.
- **Non-invasive administration:** Eliminates the need for needles, enhancing patient compliance【18】.
- **Controlled release:** Maintains steady plasma drug levels, reducing dosing frequency and side effects【19】.
- **Convenience for chronic therapies:** Ideal for conditions requiring long-term medication, such as hormone replacement therapy【20】.

6. Limitations of TDDS

Despite its benefits, TDDS has inherent challenges:

- **Restricted drug selection:** Suitable only for drugs with low molecular weight, adequate lipophilicity, and potent pharmacological effects【21】.
- **Skin irritation:** Prolonged application can cause irritation or allergic reactions in sensitive individuals【22】.
- **Limited dosing capacity:** Only small amounts of drug can be delivered effectively【23】.

7. Types of TDDS

TDDS can be classified into:

1. **Reservoir Systems:** Drug is stored in a reservoir, with a membrane controlling release. This system ensures zero-order kinetics【24】.
2. **Matrix Systems:** The drug is dispersed within a polymer matrix, simplifying manufacturing but offering less precise control【25】.
3. **Micro-reservoir Systems:** Combines reservoir and matrix features for improved performance【26】.
4. **Adhesive Matrix Systems:** Drug is integrated into the adhesive layer for direct skin contact and rapid onset of action【27】.

8. Recent Innovations in TDDS

Several advanced technologies have expanded the capabilities of TDDS:

- **Microneedles:** These tiny needles penetrate the stratum corneum, enabling the delivery of large molecules like insulin and vaccines【28】.
- **Iontophoresis:** Utilizes mild electrical currents to drive charged drug molecules through the skin, suitable for hydrophilic drugs【29】.
- **Sonophoresis:** Uses ultrasound waves to temporarily disrupt the skin barrier, enhancing drug penetration【30】.
- **Nanocarriers:** Liposomes, niosomes, and nanoparticles are being explored to improve drug stability and enhance skin permeability【31】.

9. Applications of TDDS

TDDS has found widespread use in various therapeutic areas:

- **Analgesia:** Fentanyl patches are widely used for chronic pain management in cancer patients【32】.

- **Hormone therapy:** Estradiol and testosterone patches are used for hormone replacement therapy in menopause and hypogonadism【33】.
- **Smoking cessation:** Nicotine patches help individuals quit smoking by maintaining steady plasma nicotine levels【34】.
- **Neurological disorders:** Rotigotine patches offer continuous drug delivery for Parkinson's disease management【35】.

10. Challenges and Future Perspectives

Overcoming the skin's barrier properties remains a significant challenge for TDDS. Future research is focused on developing more efficient penetration enhancers and advanced delivery systems, such as hybrid technologies combining microneedles and nanocarriers【36】. Personalized TDDS, incorporating patient-specific drug formulations and wearable technology, also represents an exciting avenue【37】.

11. Conclusion

Transdermal Drug Delivery Systems have revolutionized systemic drug administration by offering controlled, non-invasive, and patient-friendly solutions. While challenges remain, ongoing advancements promise to broaden the scope of TDDS, ensuring its relevance in future pharmaceutical therapies.

References

1. Guy RH, Hadgraft J. Transdermal drug delivery: Developmental issues and research initiatives. *Marcel Dekker Inc.* 2003.
2. Prausnitz MR, Langer R. Transdermal drug delivery. *Nature Biotechnology*. 2008;26(11):1261-1268.
3. Brown MB, et al. Dermal and transdermal drug delivery systems: Current and future prospects. *Drug Delivery Systems*. 2006;23:601-620.
4. Chien YW. Transdermal controlled systemic medications. *Marcel Dekker Inc.* 1987.
5. Prausnitz MR, et al. Current status and future potential of transdermal drug delivery. *Nature Reviews Drug Discovery*. 2004;3(2):115-124.
6. Arora P, Mukherjee B. Design, development, physicochemical, and in vitro evaluation of transdermal patches. *Acta Pharmaceutica*. 2002;52(3):189-201.
7. Cleary GW. Transdermal delivery systems: A medical rationale. *Drugs and the Pharmaceutical Sciences*. 1984;18:227–271.
8. Prausnitz MR. Microneedles for transdermal drug delivery. *Advanced Drug Delivery Reviews*. 2004;56(5):581-587.

9. Barry BW. Drug delivery routes in skin: A novel approach to drug delivery. *Advanced Drug Delivery Reviews*. 2001;54(Suppl 1):31-40.
10. Potts RO, Guy RH. Predicting skin permeability. *Pharmaceutical Research*. 1992;9(5):663-669.
11. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. *Advanced Drug Delivery Reviews*. 2002;54(Suppl 1):41-55.
12. Shah SS, Prajapati ST, Patel CN. Matrix type transdermal drug delivery system: A review. *Journal of Pharmacy Research*. 2011;4(6):1339-1345.
13. Chien YW. Novel drug delivery systems. *CRC Press*. 1992;2nd edition.
14. Jain NK. Advances in controlled and novel drug delivery. *CBS Publishers & Distributors*. 2001;1st edition: 428-431.
15. Pandey S, et al. Transdermal drug delivery system: A review. *International Journal of Pharmaceutics and Drug Analysis*. 2014;2(4):169-175.
16. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. *Churchill Livingstone*. 2017;5th edition.
17. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: Overcoming the skin's barrier function. *Pharmaceutical Science & Technology Today*. 2000;3(9):318-326.
18. Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. *Drug Development and Industrial Pharmacy*. 2000;26(11):1131-1140.
19. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. *Advanced Drug Delivery Reviews*. 2004;56(5):619-658.
20. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. *Science*. 1995;269(5225):850-853.
21. Flynn GL, et al. Transdermal delivery of captopril: Permeability and system design. *Pharmaceutical Research*. 1989;6(12):988-990.
22. Walters KA, Roberts MS. The structure and function of skin. *Dermal Absorption and Toxicity Assessment*. Marcel Dekker Inc., 2002.
23. Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synergistic action of chemicals. *Biochimica et Biophysica Acta (BBA)*. 2009;1788(11):2362-2373.
24. Cleary GW. Transdermal controlled-release systems. *Drugs and the Pharmaceutical Sciences*. 1984;18:237-268.
25. Seth AK, et al. Transdermal drug delivery system: A review. *International Journal of Drug Development and Research*. 2010;2(4):756-772.
26. Chein YW, Maibach HI. Transdermal Drug Delivery. *Drugs and the Pharmaceutical Sciences*. 1992;123:335-379.
27. Jalwal P, et al. Transdermal patches: A review on transdermal drug delivery system. *International Journal of Pharmaceutical Sciences*. 2011;2(2):26-34.

28. Prausnitz MR. Microneedles for transdermal drug delivery. *Advanced Drug Delivery Reviews*. 2004;56(5):581-587.
29. Riviere JE. Iontophoresis for drug delivery: History and applications. *Advanced Drug Delivery Reviews*. 1993;9(2-3):239-251.
30. Escoffre JM, Bouakaz A. Therapeutic ultrasound. *Advances in Experimental Medicine and Biology*. 2016;880:39-66.
31. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: From drug delivery to model membranes. *European Journal of Pharmaceutical Sciences*. 2008;34(4-5):203-222.
32. Portenoy RK, et al. Transdermal fentanyl for cancer pain: A preliminary study. *Journal of Pain and Symptom Management*. 1993;8(6):367-374.
33. Sitruk-Ware R. Transdermal delivery of contraceptives and estrogen/progestin hormone replacement therapy for postmenopausal women. *Contraception*. 2007;75(6):398-403.
34. Stead LF, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews*. 2012;11:CD000146.
35. Oertel WH, et al. Transdermal rotigotine: A novel approach to Parkinson's disease treatment. *Neurology*. 2007;68(17):1262-1267.
36. Gupta J, Prausnitz MR. Combination of microneedles and nanoparticles for transdermal drug delivery. *Expert Opinion on Drug Delivery*. 2011;8(4):459-479.
37. Vaddiraju S, et al. Technologies for continuous glucose monitoring: Current problems and future promises. *Journal of Diabetes Science and Technology*. 2010;4(6):1540-1562.